

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Genuneit, J;Jayasinghe, S;Riggioni, C;Peters, RL;Chu, DK;Munblit, D;Boyle, RJ;Du Toit, G;Skypala, I;Santos, AF;Akdis, CA;Alvarez-Perea, A;Lozano, MA;Asero, R;Ballmer-Weber, B;Barber, D;Barni, S;Pajno, GB;Beyer, K;Bindslev-Jensen, C;Brough, H;Buyuktiryaki, B;de Oliveira, LCL;Cianferoni, A;Chinthrajah, RS;Parker, SN;Giacco, SD;DunnGalvin, A;Eberlein, B;Ebisawa, M;Eigenmann, P;Eiwegger, T;Faber, M;Fernandez-Rivas, M;Feeney, M;Fisher, H;Giovannini, M;Halcken, S;Hoffmann-Sommergruber, K;Jaumdally, H;Jones, CJ;Knibb, R;Knol, E;Konstantinou, GN;Krawiec, M;Lau, S;Mayorga, L;Marques-Mejias, MA;Meyer, R;Moya, B;Mortz, CG;Muraro, A;Nadeau, K;Parker, N;Nilsson, C;O'Mahony, L;Papadopoulos, NG;Perrett, K;Piletta-Zanin, A;Podestà, M;Poulsen, LK;Ricci, C;Roberts, G;Sampson, H;Smolińska, S;Schwarze, J;Untersmayr, E;Ree, RV;Venter, C;Vickery, BP;Vlieg-Boerstra, B

Title:

Protocol for a systematic review of the diagnostic test accuracy of tests for IgE-mediated food allergy

Date:

2022-01-01

Citation:

Genuneit, J., Jayasinghe, S., Riggioni, C., Peters, R. L., Chu, D. K., Munblit, D., Boyle, R. J., Du Toit, G., Skypala, I., Santos, A. F., Akdis, C. A., Alvarez-Perea, A., Lozano, M. A., Asero, R., Ballmer-Weber, B., Barber, D., Barni, S., Pajno, G. B., Beyer, K. ,... Vlieg-Boerstra, B. (2022). Protocol for a systematic review of the diagnostic test accuracy of tests for IgE-mediated food allergy. *Pediatric Allergy and Immunology*, 33 (1), <https://doi.org/10.1111/pai.13684>.

Persistent Link:

<https://hdl.handle.net/11343/299176>

1

2 DR JON GENUNEIT (Orcid ID : 0000-0001-5764-1528)

3 DR CARMEN RIGGIONI (Orcid ID : 0000-0002-8745-0228)

4 DR RACHEL LOUISE PETERS (Orcid ID : 0000-0002-2411-6628)

5 DR DEREK K CHU (Orcid ID : 0000-0001-8269-4496)

6 DR DANIEL MUNBLIT (Orcid ID : 0000-0001-9652-6856)

7 DR ROBERT J BOYLE (Orcid ID : 0000-0002-4913-7580)

8 DR ALEXANDRA SANTOS (Orcid ID : 0000-0002-7805-1436)

9

10

11 Article type : Original Article

12

13

14 **Protocol for a systematic review of the diagnostic test accuracy of tests for IgE-mediated food**  
15 **allergy**

16

17 Jon Genuneit<sup>1</sup>, Sashini Jayasinghe<sup>2</sup>, Carmen Riggioni<sup>3</sup>, Rachel L. Peters<sup>4,5</sup>, Derek K. Chu<sup>6</sup>, Daniel  
18 Munblit<sup>7,8</sup>, Robert J. Boyle<sup>8</sup>, George Du Toit<sup>2,9,10</sup>, Isabel Skypala<sup>11</sup>, Alexandra F. Santos<sup>2,9,10,12</sup> *on behalf*  
19 *of the EAACI Food Allergy Guidelines Expert Group and the EAACI Research and Outreach Committee*  
20 *Food Allergy Group\**

21

22 <sup>1</sup>Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig,  
23 Germany24 <sup>2</sup>Department of Women and Children's Health, School of Life Course Sciences, Faculty of Life  
25 Sciences and Medicine, King's College London, London, UK26 <sup>3</sup>Allergy and Clinical Immunology, Department of Paediatrics, Yong Loo Lin School of Medicine,  
27 National University of Singapore28 <sup>4</sup>Murdoch Children's Research Institute, Parkville, Victoria, Australia29 <sup>5</sup>Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/PAI.13684](https://doi.org/10.1111/PAI.13684)

This article is protected by copyright. All rights reserved

30 <sup>6</sup>Department of Medicine and Department of Health Research Methods, Evidence & Impact,  
31 McMaster University, Canada

32 <sup>7</sup>Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov  
33 First Moscow State Medical University (Sechenov University), Moscow, Russia

34 <sup>8</sup>Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of  
35 Medicine, Imperial College London, London, United Kingdom

36 <sup>9</sup>Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's  
37 College London, London, UK

38 <sup>10</sup>Children's Allergy Service, Evelina London, Guy's and St Thomas' Hospital, London, UK

39 <sup>11</sup>Department of Allergy and Clinical Immunology, Royal Brompton and Harefield NHS Foundation  
40 Trust, London, UK

41 <sup>12</sup>Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK

42

43 **Corresponding Author:**

44 Jon Genuneit

45 Pediatric Epidemiology

46 Department of Pediatrics

47 Medical Faculty, Leipzig University

48 Liebigstr. 20a, Haus 6

49 D-04103 Leipzig

50 GERMANY

51 Jon.genuneit@medizin.uni-leipzig.de

52

53 **\*Full list of contributors:**

54 Cezmi A. Akdis<sup>13</sup>, Alberto Alvarez-Perea<sup>14</sup>, Montserrat Alvaro Lozano<sup>15</sup>, Riccardo Asero<sup>16</sup>, Barbara

55 Ballmer-Weber<sup>17,18</sup>, Domingo Barber<sup>19,20</sup>, Simona Barni<sup>21</sup>, Giovanni Battista Pajno<sup>22</sup>, Kirsten Beyer<sup>23</sup>,

56 Carsten Bindslev-Jensen<sup>24</sup>, Helen Brough<sup>25, 26, 27</sup>, Betul Buyuktiryaki<sup>28</sup>, Lucila Camargo Lopes de

57 Oliveira<sup>29</sup>, Antonella Cianferoni<sup>30</sup>, R Sharon Chinthrajah<sup>31,32</sup>, Stefano Del Giacco<sup>33</sup>, Audrey

58 DunnGalvin<sup>34,35,36</sup>, Bernadette Eberlein<sup>37</sup>, Motohiro Ebisawa<sup>38</sup>, Philippe Eigenmann<sup>39</sup>, Thomas

59 Eiwegger<sup>40,41,42</sup>, Margaretha Faber<sup>43</sup>, Montserrat Fernandez-Rivas<sup>44</sup>, Mary Feeney<sup>26,27</sup>, Helen Fisher<sup>27</sup>,

60 Mattia Giovannini<sup>45</sup>, Susanne Halcken<sup>46</sup>, Karin Hoffmann-Sommergruber<sup>47</sup>, Hannah Jaumdally<sup>27</sup>,

61 Christina J Jones<sup>48</sup>, Rebecca Knibb<sup>49</sup>, Edward Knol<sup>50</sup>, George N Konstantinou<sup>51</sup>, Marta Krawiec<sup>26,27</sup>,

62 Susanne Lau<sup>52</sup>, Lina Mayorga<sup>53</sup>, M. Andreina Marques-Mejias<sup>26,27</sup>, Rosan Meyer<sup>54</sup>, Beatriz Moya<sup>55</sup>,  
63 Charlotte G Mortz<sup>24</sup>, Antonella Muraro<sup>56</sup>, Kari Nadeau<sup>31,32</sup>, Caroline Nilsson<sup>57,58</sup>, Liam O'Mahony<sup>59</sup>,  
64 Nikolaos G. Papadopoulos<sup>60,61</sup>, Kirsten Perrett<sup>62</sup>, Alexandre Piletta-Zanin<sup>39</sup>, Marcia Podestà<sup>63</sup>, Lars K.  
65 Poulsen<sup>64</sup>, Cristian Ricci<sup>1</sup>, Graham Roberts<sup>65,66</sup>, Hugh Sampson<sup>67</sup>, Sylwia Smolińska<sup>68</sup>, Jürgen  
66 Schwarze<sup>69</sup>, Eva Untersmayr<sup>70</sup>, Ronald Van Ree<sup>71</sup>, Carina Venter<sup>72</sup>, Brian P. Vickery<sup>73</sup>, Berber Vlieg-  
67 Boerstra<sup>74</sup>

68 <sup>13</sup> Swiss Institute of Allergy and Asthma Research

69 <sup>14</sup> Hospital General Universitario Gregorio Marañón, Madrid, Spain

70 <sup>15</sup> Pediatric Allergy and Clinical Immunology Service, Hospital Sant Joan de Déu, Barcelona

71 <sup>16</sup> Clinica San Carlo, Paderno Dugnano, Italy

72 <sup>17</sup> Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland;  
73 Faculty of Medicine, University of Zurich, Zurich, Switzerland

74 <sup>18</sup> Clinic for Dermatology and Allergology, Kantonsspital St Gallen, St Gallen, Switzerland.

75 <sup>19</sup> School of Medicine, Institute for Applied Molecular Medicine (IMMA), Universidad CEU San Pablo,  
76 Madrid, Spain.

77 <sup>20</sup> Instituto de Salud Carlos III, Madrid, Spain

78 <sup>21</sup> Meyer Children's University Hospital, Florence, Italy

79 <sup>22</sup> Pediatric Unit, Policlinico Hospital. University of Messina-Italy

80 <sup>23</sup> Charité Universitätsmedizin Berlin, Germany

81 <sup>24</sup> Odense University Hospital, Odense Denmark

82 <sup>25</sup> Evelina London Childrens Hospital, London, UK

83 <sup>26</sup> Guy's and St Thomas' Hospital London, UK

84 <sup>27</sup> King's College London, UK

85 <sup>28</sup> Koc University Hospital, Istanbul, Turkey

- 86 <sup>29</sup> Federal University of São Paulo, Brazil
- 87 <sup>30</sup> Department of Pediatrics, Division of Allergy and Immunology, The Children's Hospital of  
88 Philadelphia, PA, USA
- 89 <sup>31</sup> Sean N Parker Center for Allergy and Asthma Research, Stanford University, USA
- 90 <sup>32</sup> Pulmonary, Allergy, Critical Care Medicine, Department of Medicine, Stanford University, USA
- 91 <sup>33</sup> Department of Medical Sciences and Public Health, University of Cagliari, Italy
- 92 <sup>34</sup> University College Cork, Ireland
- 93 <sup>35</sup> Anaphylaxis Ireland (CEO)
- 94 <sup>36</sup> Sechenov University, Moscow
- 95 <sup>37</sup> Department of Dermatology and Allergy Biederstein Technische Universität München
- 96 <sup>38</sup> Department of Allergy, Clinical Research Center for Allergy and Rheumatology, Sagami-hara  
97 National Hospital, Kanagawa, Japan
- 98 <sup>39</sup> University Hospitals of Geneva, Switzerland
- 99 <sup>40</sup> The Hospital for Sick Children, Toronto, Ontario
- 100 <sup>41</sup> University of Toronto, Ontario
- 101 <sup>42</sup> University Hospital of St. Pölten, Karl Landsteiner University of Health Sciences
- 102 <sup>43</sup> University of Antwerp, Department of Immunology and Allergology, Antwerp, Belgium
- 103 <sup>44</sup> Allergy Dept., Hospital Clinico San Carlos, Universidad Complutense, IdISSC, Madrid, Spain
- 104 <sup>45</sup> Meyer Children's University Hospital, Florence, Italy
- 105 <sup>46</sup> Hans Christian Andersen Children's Hospital, Odense University Hospital
- 106 <sup>47</sup> Medical University of Vienna, Austria
- 107 <sup>48</sup> University of Surrey, Guildford, UK
- 108 <sup>49</sup> Department of Psychology, Aston University, Birmingham, UK.

- 109 <sup>50</sup> Departments of Immunology and Dermatology/Allergology, University Medical Center Utrecht,  
110 Utrecht, the Netherlands
- 111 <sup>51</sup> Department of Allergy and Clinical Immunology General Military Training Hospital, Thessaloniki,  
112 Greece
- 113 <sup>52</sup> Universitaetsmedizin Berlin, Pediatric Respiratory Medicine, Immunology and Intensive Care  
114 Medicine, Germany
- 115 <sup>53</sup> Biomedical Research Institute and University Hospital of Málaga
- 116 <sup>54</sup> Imperial College London UK
- 117 <sup>55</sup> Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
- 118 <sup>56</sup> Food Allergy Referral Centre, Department of Woman and Child Health, Padua University hospital ,  
119 Padua , Italy
- 120 <sup>57</sup> Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm,  
121 Sweden
- 122 <sup>58</sup> Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden
- 123 <sup>59</sup> University College Cork, Cork, Ireland
- 124 <sup>60</sup> Allergy Department, 2nd Pediatric Clinic, University of Athens, Greece
- 125 <sup>61</sup> Division of Infection, Immunity & Respiratory Medicine, University of Manchester, UK
- 126 <sup>62</sup> Murdoch Children's Research Institute, Melbourne, Australia
- 127 <sup>63</sup> European Federation of Allergy and Airways Diseases Patient's Associations, Belgium
- 128 <sup>64</sup> Copenhagen University Hospital, Denmark
- 129 <sup>65</sup> David Hide Centre, St Mary's Hospital, Isle of Wight, United Kingdom
- 130 <sup>66</sup> University of Southampton, Southampton, United Kingdom
- 131 <sup>67</sup> Department of Pediatrics at the Icahn School of Medicine at Mount Sinai
- 132 <sup>68</sup> Wroclaw Medical University, Department of Clinical Immunology, Wroclaw, Poland

133 <sup>69</sup> The University of Edinburgh, Edinburgh, UK

134 <sup>70</sup> Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and  
135 Immunology, Medical University of Vienna

136 <sup>71</sup> Amsterdam University Medical Centers, Location AMC, The Netherlands

137 <sup>72</sup> Children's Hospital Colorado, University of Colorado, Colorado, USA

138 <sup>73</sup> Emory University and Children's Healthcare of Atlanta

139 <sup>74</sup> OLVG Hospital, Amsterdam, the Netherlands

140 **Abstract** (237 words)

141 **Background:** The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of  
142 updating the guidelines on the diagnosis and management of food allergy. The existing guidelines  
143 are based on a systematic review of the literature until 30<sup>th</sup> September 2012. Therefore, a new  
144 systematic review must be undertaken to inform the new guidelines. This systematic review aims to  
145 assess the accuracy of index tests to support the diagnosis of IgE-mediated food allergy.

146 **Methods:** The databases Cochrane CENTRAL (Trials), MEDLINE (OVID) and Embase (OVID) will be  
147 searched for diagnostic test accuracy studies from 1<sup>st</sup> October 2012 to 30<sup>th</sup> June 2021. Inclusion and  
148 exclusion criteria will be used to select appropriate studies. Data from these studies will be extracted  
149 and tabulated, and then reviewed for risk of bias and applicability using the QUADAS-2 tool. All  
150 evaluation will be done in duplicate. Studies with a high risk of bias and low applicability will be  
151 excluded. Meta-analysis will be performed if there are three or more studies of the same index test  
152 and food.

153 **Results:** A protocol for the systematic review and meta-analyses is presented and was registered  
154 using Prospero prior to commencing the literature search.

155 **Discussion:** Oral food challenges are the reference standard for diagnosis but involve considerable  
156 risks and resources. This protocol for systematic review aims to assess the accuracy of various tests  
157 to diagnose food allergy, which can be useful in both clinical and research settings.

158

159 **Key message:** The protocol for the systematic review of the literature about the accuracy of index  
160 tests to support the diagnosis of IgE-mediated food allergy is presented and this systematic review  
161 will inform the update of the guidelines on the diagnosis and management of food allergy of the  
162 European Academy of Allergy and Clinical Immunology (EAACI).

163

164

165 **Keywords:** basophil activation test, component-resolved diagnostics, diagnosis, diagnostic tests, food  
166 allergy, IgE-mediated, mast cell activation test, skin prick test, specific IgE

## 167 **Background**

168 The global prevalence of food allergy is about 10% with an increase in its incidence in the last 20-30  
169 years<sup>1,2</sup>. Food allergies are more common in Westernized countries, affecting children more than  
170 adults<sup>3</sup>. Any food can be a potential allergen; however, a large proportion of food allergies are  
171 caused by cow's milk, egg, wheat, soya, peanut, tree nuts, fish and shellfish. There are, however,  
172 geographic differences<sup>4</sup> – for instance, while peanut allergy is relatively common in the UK, USA,  
173 Canada and Australia, it is very rarely seen in Africa and Asia, excluding Japan. Overall, cow's milk  
174 and egg allergies appear to be the most common food allergies in young children in the UK and  
175 most parts of Europe, USA, Canada, Asia and Australia<sup>5</sup>.

176 Food allergies can be classified as immunoglobulin E (IgE) mediated and non-IgE mediated, with the  
177 former being the most common and the focus of this systematic review. IgE-mediated food allergies  
178 usually induce immediate reactions, i.e. reactions that occur up to 2 hours (usually a few minutes)  
179 after exposure to the allergen, and these can be severe, and sometimes life-threatening. By contrast,  
180 non-IgE mediated allergies prompt a delayed response, with symptoms taking up to two days to  
181 evolve, or manifest chronically<sup>6</sup>. Clinical manifestations of food allergy include skin, gastrointestinal  
182 (GI) and respiratory reactions, with skin reactions being the most prevalent and presenting as  
183 urticaria, angioedema and erythema<sup>7,8</sup>. GI symptoms include abdominal pain, diarrhoea, nausea and  
184 vomiting. Rhinorrhoea, nasal obstruction, bronchospasm and oedema of the larynx are possible  
185 respiratory symptoms<sup>2</sup>. Allergic reactions can vary in severity, ranging from local reactions such as  
186 tingling in the mouth to anaphylaxis, a severe life-threatening allergic reaction affecting breathing or  
187 circulation<sup>8,9</sup>.

188 The diagnosis of IgE-mediated food allergy is usually based on the clinical presentation and evidence  
189 of IgE sensitisation to the specific allergen, as documented by skin prick test (SPT) or serum specific  
190 IgE<sup>10</sup>. The gold standard to diagnose food allergy is the oral food challenge (OFC), in which the  
191 suspected food is administered orally in gradually increasing doses until either a reaction occurs or  
192 all doses are consumed without developing any symptoms. The OFC can be used to confirm the  
193 diagnosis, to assess tolerability in people with a confirmed allergy, or to detect the reaction  
194 threshold. In cases with a recent history of an allergic reaction, detectable IgE specific to the culprit  
195 allergen can be enough to confirm the diagnosis, dispensing OFC. OFC is associated with the risk of  
196 an allergic reaction of variable severity. OFC are resource-intensive as they must be conducted in a  
197 controlled environment with intensive care facilities in easy reach, and not all clinical settings can

198 offer this service. Additionally, this risk of reaction may lead to significant anxiety in patients and  
199 their families, therefore a reliable and cost-effective alternative to OFC is needed.

200 Several tests have been used to support the diagnosis of food allergy, namely SPT, specific IgE and  
201 cellular tests. SPT and sIgE detect the presence of IgE antibodies to a particular food. They detect  
202 allergic sensitisation, which does not necessarily correlate to a clinical reaction. Approximately half  
203 of children sensitised to a food are able to tolerate it without reaction. SPT and sIgE therefore  
204 generally have high sensitivity but poor specificity to diagnose food allergy. Increasing magnitude of  
205 these tests are associated with increased risk of clinical reaction, and thresholds with high  
206 probability of food allergy have been identified for some foods (e.g. for peanut: SPT  $\geq 8$ mm or sIgE  
207  $\geq 15$  have 95%PPV) which preclude the need for OFC in some settings. Reported thresholds vary in  
208 the literature, likely due to differences in study design and patient characteristics. Component-  
209 resolved diagnosis (CRD) refers to the determination of specific IgE levels to specific proteins in  
210 food<sup>11</sup>. Cellular tests include the basophil activation test (BAT) and the mast cell activation test  
211 (MAT); however these are currently not used in routine clinical practice. CRD are becoming more  
212 routine practice and have high specificity for some foods. BAT and MAT offer an improvement on  
213 sensitivity and specificity compared to traditional SPT or sIgE tests.

214 The European Academy of Allergy and Clinical Immunology (EAACI) is currently in the process of  
215 updating their food allergy guidelines. Thus, systematic reviews of existing literature will be carried  
216 out to inform the new guidelines. This systematic review aims to assess the diagnostic accuracy  
217 measured by sensitivity and specificity of index tests for IgE-mediated food allergy compared to the  
218 gold-standard OFC. Furthermore, comparison among index tests will be conducted if sufficient  
219 evidence is available.

220

## 221 **Methods**

222 Research question

223 We defined the question overarching to the systematic review in the PICO format (**Box 1**) and  
224 describe its components in the sections below.

225

### 226 Search strategy

227 Search terms are indicated in **Table 1**. The following databases will be searched:

- 228 • Cochrane CENTRAL (Trials)
- 229 • MEDLINE (OVID)
- 230 • Embase (OVID)

231 These databases will be searched for entries between the period of 1<sup>st</sup> October 2012 to the 31<sup>st</sup> May  
232 2021. This aligns with the end date of the search entries used in a previous systematic review on the  
233 same subject<sup>12</sup>. Studies which were published earlier and included in the previous systematic review  
234 will be evaluated for inclusion in the current systematic review. Forward and backward citation  
235 analysis will be used in all included studies to pinpoint other relevant studies. Any additional studies  
236 discovered by the review team who are experts in the field may be included. Only published, peer-  
237 reviewed full reports will be included.

238

#### 239 Condition/domain being studied

240 The main domain being investigated is IgE-mediated food allergy. We will explore any food allergen.  
241 Food allergens will be ranked by the frequency of available studies and index test, with the most  
242 commonly investigated allergen prioritised, if necessary. This is because we will assume that more  
243 studies will raise more high-quality studies, thus firming evidence. Next, the more recently  
244 developed tests (CRD, BAT, MAT) will be prioritised according to the frequency of reports. The  
245 previous EAACI Food Allergy Guideline paper has already given recommendations for SPT and  
246 specific IgE, and we aim to summarise novel evidence on SPT and specific IgE if this seems  
247 warranted.

248

#### 249 Population

250 Studies of children and adults, irrespective of age, with suspected IgE-mediated allergy to any food  
251 will be considered.

252

#### 253 Interventions

254 Any index tests to diagnose food allergy in the included studies will be reported. Priority will be  
255 placed on the more recently developed test strategies of specific IgE to allergen components, BAT  
256 and MAT as described above.

257

#### 258 Comparator

259 The comparator to define the accuracy for immediate-type food allergy diagnosis will be OFC,  
260 including both open food challenge or double-blind placebo-controlled food challenge, performed in  
261 at least a proportion of study participants.

262

#### 263 Inclusion criteria

264 Studies fulfilling the following criteria will be included:

- 265 • Studies containing sufficient data to calculate sensitivity and specificity, to get a measure of  
266 the diagnostic accuracy.
- 267 • Diagnostic test studies with any sequence of index test and reference standard test  
268 performed and with any algorithm or procedure of participant selection. These  
269 characteristics will be part of the risk of bias assessment and evaluation of reasons for  
270 heterogeneity as laid out below.

271

#### 272 Exclusion criteria

273 Studies fulfilling the following criteria will be excluded:

- 274 • Conference abstracts
- 275 • Narrative reviews, editorials and correspondence
- 276 • Systematic reviews (reference lists will first be scanned for relevant original articles)
- 277 • Qualitative studies
- 278 • Case reports and case series
- 279 • Animal studies
- 280 • Studies in which allergies are defined based on sensitization tests alone without a history  
281 following ingestion.
- 282 • Studies may be excluded based on risk of bias and applicability

283 Each study will be screened by two reviewers independently based on the title and abstract  
284 according to the inclusion and exclusion criteria (described below). If there are any discrepancies  
285 between the reviewers, a third reviewer will adjudicate. When the studies have been selected, the  
286 full texts will be reviewed to confirm they meet the inclusion criteria. Data will be extracted from  
287 these studies and the quality will be assessed for risk of bias and applicability. Studies which satisfy  
288 the inclusion criteria but are not in English will be translated prior to data extraction and quality  
289 assessment.

290

#### 291 Data extraction and management

292 The details that will be collected from the selected studies are represented in **Box 2**. Data extraction  
293 will be conducted by two independent reviewers and subsequently recorded using COVIDENCE. Any  
294 discrepancies will be resolved by a third reviewer.

295

#### 296 Quality assessment (risk of bias)

297 All included studies will be assessed for risk of bias and their applicability based on the QUADAS 2  
298 instrument<sup>13</sup>. The four key domains covering patient selection, index test, reference standard

299 (comparator), and flow and timing will be evaluated. Any studies deemed to have a high risk of bias  
300 i.e. scoring 'high' for three or more of the four risk of bias domains, or concerns regarding  
301 applicability i.e. scoring 'high' for two or more of the three applicability domains will be excluded  
302 from further meta-analyses.

303

#### 304 Strategy for data synthesis

305 When possible, data extracted for sensitivity and specificity will be analysed using random effects  
306 meta-analysis using hierarchical summary receiver operating characteristic (ROC) curve analysis in  
307 case of three or more studies for a given combination of index test and food.

308 The GRADE approach will be used to assess heterogeneity<sup>14,15</sup>, and will not solely rely on statistical  
309 methods such as the  $I^2$  statistic. Depending on the included studies, the following reasons for  
310 heterogeneity will be discussed:

- 311 • Multiple definitions of target condition
- 312 • Multiple thresholds of test positivity for index and/or comparator
- 313 • Age of the participants
- 314 • Origin of study population as indication for patient spectrum/pre-test probability
- 315 • All domains of risk of bias of the included studies

316 The GRADE approach will be used to evaluate the certainty of the body of evidence.

317

#### 318 Sensitivity analysis

319 Sensitivity analysis may be carried out if three or more studies are retained for a given combination  
320 of index test and food allergen following exclusion of studies which are suspected to contribute to  
321 heterogeneity or limiting to studies with low risk of bias, i.e. studies with 'low' in all four risk of bias  
322 domains of the QUADAS-2.

323

#### 324 Dissemination plans

325 The final report will be published in one of the scientific journals affiliated with EAACI and will be  
326 used to inform the update of the EAACI Guidelines on Food Allergy. The findings of the systematic  
327 review will be presented at scientific conferences, namely the EAACI annual congress and at the  
328 EAACI Food Allergy and Anaphylaxis Meeting. A summary of the findings will be made available in lay  
329 language on the EAACI website.

330

#### 331 **Discussion**

332 The EAACI Food Allergy Guidelines need to be updated, including the section on diagnostic tests for  
333 food allergy. The systematic review of the literature on diagnostic tests that informed the current  
334 EAACI Food Allergy Guidelines was conducted prior to 2014, thus a new systematic review is needed,  
335 especially since new and emerging tests such as CRD, MAT and BAT were not included in the  
336 previous review. We report herein the protocol for a systematic review of the literature, as  
337 registered at PROSPERO (CRD42021259186), and provide a description of the rationale and methods  
338 chosen for the review.

339 Since the previous guideline was published, newer tests such as CRD have entered mainstream use  
340 in Europe and other regions<sup>16-19</sup>. Also, studies assessing the efficacy of novel diagnostic tests such as  
341 BAT and MAT have been published<sup>20-29</sup>. All of these new tests must be reviewed to assess whether  
342 they are acceptable diagnostic tools for use in routine clinical practice. For more established allergy  
343 tests, such as SPT and sIgE, new studies have been performed since the previous review which may  
344 require updating of the previous recommendation. We aim to evaluate the diagnostic test accuracy  
345 of any index test, from SPT, sIgE to extracts, sIgE to individual allergens, sIgE to allergen peptides,  
346 BAT and MAT. Thus, we do not include search terms for the index test. We apply a specific filter for  
347 diagnostic test accuracy studies, though, which implicitly captures studies on diagnostics and/or  
348 tests. We only include search terms for “challenge” as part of the common terminology for the  
349 comparator, i.e. oral food challenge, to have a sensitive search regarding the comparator test.

350 The population of interest will include all ages and diverse clinical settings and geographical  
351 locations. We deliberately do not include search terms to specify the target population and studies  
352 that do not have evidence from all populations will be included in the review and judged for risk of  
353 bias. We expect to encounter very few if any diagnostic test accuracy studies conducted in animals;  
354 however, we will refrain from specifying search terms that will exclude animal studies because of the  
355 risk of falsely excluding studies on animal allergen sources. Certain food allergies are more prevalent  
356 in different areas. As such, we will include studies focussing on any food, to be inclusive to all  
357 populations, although we anticipate that there will be more studies on milk, egg and peanut  
358 allergies.

359 Although the gold standard is DBPCFC, we will also include studies where open oral food challenges  
360 are performed and allow for the inclusion of studies where a small proportion of patients were  
361 diagnosed without an oral food challenge due to previous severe or anaphylactic reactions. Studies  
362 focusing only on IgE sensitisation will be excluded, as some patients who experience sensitisation to  
363 foods are not necessarily allergic. It is important to note that the comparator reference standard test  
364 is oral food challenge and as such, the systematic review will inform on the diagnostic accuracy of

365 potential alternative tests. However, the systematic review will not clarify which of these tests is  
366 best used in subjects in whom the oral food challenge is contraindicated.  
367 As outcomes we are assessing sensitivity and specificity as measures of diagnostic test accuracy. The  
368 positive and negative predictive value of the test, which depends on the prevalence of the given  
369 food allergy in the population, is not within the scope of this systematic review. The details collected  
370 as part of the quality assessment and risk of bias will allow us to select high-quality studies at low  
371 risk of bias. The planned sensitivity analyses on these features may help to identify factors that  
372 influence the performance of the test and the modulation of the identified diagnostic cut-offs. If  
373 sufficient high quality studies are identified, the planned meta-analyses will provide evidence which  
374 may help to reduce the number of patients that have to undergo an OFC procedure.  
375 In conclusion, we present and discuss herein the protocol that we have developed for the systematic  
376 review of the literature and meta-analyses on the use of diagnostic tests to support the diagnosis of  
377 food allergy, aiming to use all relevant studies to summarise their diagnostic accuracy as measured  
378 by sensitivity and specificity in comparison to the allergic status determined, at least in a proportion  
379 of subjects, by OFC. We will use the results of this systematic review to inform the recommendations  
380 produced as part of the new EAACI Food Allergy Guidelines.

381

## 382 **Tables and Figures:**

383

**Question:** What is the diagnostic accuracy by means of sensitivity and specificity of any index tests for IgE-mediated food allergy compared to the reference standard of oral food challenge or previous clear history of anaphylaxis to the food and evidence of allergic sensitization?

### **PICO**

- **Population:** humans (irrespective of age) with a suspected IgE-mediated allergy to any specific food
- **Intervention:** any index test
- **Comparator:** IgE-mediated food allergy diagnosis determined by oral food challenges (but any method including open food challenge or double-blind placebo-controlled food challenge) in at least a portion of study participants.
- **Outcome:** sensitivity and specificity of the test.

384 **Box 1.** Question central to the systematic review in the PICO format

385

386

387

- Number of participants
- Age of participants
- Geographical location
- Origin of the study population (general population, outpatient clinics, interventional study)
- Study design (case-control, prospective)
- The tested food
- Index test performed with detailed methods (e.g. SPT – fresh food or extract, type of lancet used; specific IgE: ImmunoCAP, Siemens etc.; Microarray: ISAC, ALEX, BAT: commercial kit or in house method, stimulants, identification and activation markers used, outcome of BAT; MAT: cell line or primary cells, activation marker used)
- Comparator (gold-standard) and details on this test: proportion with food challenge, type of food challenge, alternative clinical diagnosis (history of IgE-mediated symptoms and allergic sensitization), blinding, placebo control, period between allergen and placebo control feeding
- Number of participants in index test group(s) and comparator group(s)
- Identified cut offs (optimal, negative, positive) or other criteria for positive test
- Raw numbers of true positives, true negatives, false-positives and false-negatives for each index test, compared to the comparator
- Sensitivity and specificity

389

390 **Table 1.** Search terms used in the systematic review.

391

	<b>Search Term (OVID)</b>	<b>Detail/Strategy</b>
1	“food hypersensit:”.mp OR “food allerg:”.mp OR “food sensit:”.mp OR “Food-dependent exercise-induced anaphylaxis”.mp OR “cow?? adj2 allerg:”.mp OR “milk adj2 allerg:”.mp OR “peanut? adj2 allerg:”.mp OR “egg? adj2 allerg:”.mp OR “nut? adj2 allerg:”.mp OR “hazelnut? adj2 allerg:”.mp OR “walnut? adj2 allerg:”.mp OR “pistachio? adj2 allerg:”.mp OR “almond? adj2 allerg:”.mp OR “brazil adj2 allerg:”.mp	Clinical condition  Most likely to be captured by the first four general search terms but augmented by terms specific for foods in combination with terms for allergy in varying order (e.g. “cashew allergy”, “cashew nut allergy”, “allergic to cashew”

	<p>OR "macadamia adj2 allerg:".mp  OR "pecan adj2 allerg:".mp  OR "cashew? adj2 allerg:".mp  OR "sesame adj2 allerg:".mp  OR "soy? adj2 allerg:".mp  OR "lentil? adj2 allerg:".mp  OR "pea? adj2 allerg:".mp  OR "chickpea? adj2 allerg:".mp  OR "rice adj2 allerg:".mp  OR "celery adj2 allerg:".mp  OR "peach adj2 allerg:".mp  OR "apple? adj2 allerg:".mp  OR "wheat adj2 allerg:".mp  OR "gluten adj2 allerg:".mp  OR "mustard adj2 allerg:".mp  OR "meat adj3 allerg:".mp  OR "beef adj2 allerg:".mp  OR "pork adj2 allerg:".mp  OR "alpha-gal adj2 allerg:".mp  OR "fish adj2 allerg:".mp  OR "seafood adj2 allerg:".mp  OR "shrimp? adj2 allerg:".mp</p>	<p>will all be captured by  "cashew adj2 allerg:")</p>
2	<p>challeng:.mp. OR provocation:.mp. OR anaphylaxis.mp</p>	<p>broad term for  reference standard  (i.e. oral food  challenge or  provocation) or  anaphylaxis in  instances when oral  challenges were not  conducted</p>
3	<p>sensitiv:.mp. OR "predictive value:".mp. OR accurac:.tw.</p>	<p>McMaster HiRU filter  with best balance of</p>

		sensitivity and specificity to identify diagnostic test accuracy studies
4	1 AND 2 AND 3	
5	MEDLINE: limit 3 to dt=20121001-20210531 EMBASE: limit 3 to dd=20121001-20210531	Date since end of the search from previous systematic review

392

393 **References:**

- 394 1. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported  
395 Childhood Food Allergies in the United States. *Pediatrics* 2018;142.
- 396 2. Baseggio Conrado A, Ierodiakonou D, Gowland MH, Boyle RJ, Turner PJ. Food  
397 anaphylaxis in the United Kingdom: analysis of national data, 1998-2018. *BMJ*  
398 2021;372:n251.
- 399 3. Sicherer SH, Sampson HA. Food allergy: A review and update on epidemiology,  
400 pathogenesis, diagnosis, prevention, and management. *J Allergy Clin Immunol* 2018;141:41-  
401 58.
- 402 4. Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in  
403 school-aged children in eight European countries - the EuroPrevall-iFAAM birth cohort.  
404 *Allergy* 2020.
- 405 5. Tham EH, Leung DYM. How Different Parts of the World Provide New Insights Into  
406 Food Allergy. *Allergy Asthma Immunol Res* 2018;10:290-9.
- 407 6. Walsh J, Meyer R, Shah N, Quekett J, Fox AT. Differentiating milk allergy (IgE and  
408 non-IgE mediated) from lactose intolerance: understanding the underlying mechanisms and  
409 presentations. *Br J Gen Pract* 2016;66:e609-11.
- 410 7. Waserman S, Begin P, Watson W. IgE-mediated food allergy. *Allergy Asthma Clin*  
411 *Immunol* 2018;14:55.
- 412 8. Lopez CM, Yarrarapu SNS, Mendez MD. Food Allergies. *StatPearls. Treasure Island*  
413 *(FL)2021.*
- 414 9. Dribin TE, Schnadower D, Spergel JM, et al. Severity grading system for acute allergic  
415 reactions: A multidisciplinary Delphi study. *J Allergy Clin Immunol* 2021.

- 416 10. Foong RX, Dantzer JA, Wood RA, Santos AF. Improving Diagnostic Accuracy in Food  
417 Allergy. *J Allergy Clin Immunol Pract* 2021;9:71-80.
- 418 11. Callery EL, Keymer C, Barnes NA, Rowbottom AW. Component-resolved diagnostics  
419 in the clinical and laboratory investigation of allergy. *Ann Clin Biochem* 2020;57:26-35.
- 420 12. Soares-Weiser K, Takwoingi Y, Panesar SS, et al. The diagnosis of food allergy: a  
421 systematic review and meta-analysis. *Allergy* 2014;69:76-86.
- 422 13. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the  
423 quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155:529-36.
- 424 14. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating  
425 quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
- 426 15. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength  
427 of recommendations for diagnostic tests and strategies. *BMJ* 2008;336:1106-10.
- 428 16. Klemans RJ, van Os-Medendorp H, Blankestijn M, Bruijnzeel-Koomen CA, Knol EF,  
429 Knulst AC. Diagnostic accuracy of specific IgE to components in diagnosing peanut allergy: a  
430 systematic review. *Clin Exp Allergy* 2015;45:720-30.
- 431 17. Nilsson C, Berthold M, Mascialino B, Orme ME, Sjolander S, Hamilton RG. Accuracy of  
432 component-resolved diagnostics in peanut allergy: Systematic literature review and meta-  
433 analysis. *Pediatr Allergy Immunol* 2020;31:303-14.
- 434 18. Nilsson C, Berthold M, Mascialino B, Orme M, Sjolander S, Hamilton R. Allergen  
435 components in diagnosing childhood hazelnut allergy: Systematic literature review and  
436 meta-analysis. *Pediatr Allergy Immunol* 2020;31:186-96.
- 437 19. Flores Kim J, McCleary N, Nwaru BI, Stoddart A, Sheikh A. Diagnostic accuracy, risk  
438 assessment, and cost-effectiveness of component-resolved diagnostics for food allergy: A  
439 systematic review. *Allergy* 2018;73:1609-21.
- 440 20. Santos AF, Douiri A, Becares N, et al. Basophil activation test discriminates between  
441 allergy and tolerance in peanut-sensitized children. *J Allergy Clin Immunol* 2014;134:645-52.
- 442 21. Santos AF, Bergmann M, Brough HA, et al. Basophil Activation Test Reduces Oral  
443 Food Challenges to Nuts and Sesame. *J Allergy Clin Immunol Pract* 2020.
- 444 22. Santos AF, Du Toit G, O'Rourke C, et al. Biomarkers of severity and threshold of  
445 allergic reactions during oral peanut challenges. *J Allergy Clin Immunol* 2020.
- 446 23. Imakiire R, Fujisawa T, Nagao M, et al. Basophil Activation Test Based on CD203c  
447 Expression in the Diagnosis of Fish Allergy. *Allergy Asthma Immunol Res* 2020;12:641-52.

- 448 24. Mehlich J, Fischer J, Hilger C, et al. The basophil activation test differentiates  
449 between patients with alpha-gal syndrome and asymptomatic alpha-gal sensitization. *J*  
450 *Allergy Clin Immunol* 2019;143:182-9.
- 451 25. Elizur A, Appel MY, Nachshon L, et al. NUT Co Reactivity - ACquiring Knowledge for  
452 Elimination Recommendations (NUT CRACKER) study. *Allergy* 2018;73:593-601.
- 453 26. Schwager C, Kull S, Behrends J, et al. Peanut oleosins associated with severe peanut  
454 allergy-importance of lipophilic allergens for comprehensive allergy diagnostics. *J Allergy*  
455 *Clin Immunol* 2017.
- 456 27. Appel MY, Nachshon L, Elizur A, Levy MB, Katz Y, Goldberg MR. Evaluation of the  
457 basophil activation test and skin prick testing for the diagnosis of sesame food allergy. *Clin*  
458 *Exp Allergy* 2018;48:1025-34.
- 459 28. Wai CYY, Leung NYH, Leung ASY, et al. Cell-Based Functional IgE Assays Are Superior  
460 to Conventional Allergy Tests for Shrimp Allergy Diagnosis. *J Allergy Clin Immunol Pract*  
461 2021;9:236-44 e9.
- 462 29. Santos AF, Couto-Francisco N, Becares N, Kwok M, Bahnson HT, Lack G. A novel  
463 human mast cell activation test for peanut allergy. *J Allergy Clin Immunol* 2018;142:689-91  
464 e9.  
465